Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : JT-09
Therapeutic Area : Dermatology
Study Phase : Undisclosed
Sponsor : Titan Pharmaceuticals Inc
Deal Size : Undisclosed
Deal Type : Acquisition
Details : Titan has acquired JT Pharma's kappa opioid agonist peptide, JT-09, for use in combination with Titan's ProNeura® long-term, continuous drug delivery technology, for the treatment of chronic pruritus.
Brand Name : JT-09
Molecule Type : Peptide
Upfront Cash : Undisclosed
October 28, 2020
Lead Product(s) : JT-09
Therapeutic Area : Dermatology
Highest Development Status : Undisclosed
Sponsor : Titan Pharmaceuticals Inc
Deal Size : Undisclosed
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?